With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Accelerating Access to Cellular Therapies for the Treatment of Childhood Malignancies||Seattle Children's Hospital and Regional Medical Center / Julie Park, MD||Phase I/II Infrastructure Grants||2013||Washington|
|Columbia University Developmental Therapeutics Program: Striving for Excellence||Columbia University / Julia Glade Bender, MD||Phase I/II Infrastructure Grants||2013||New York|
|Children's Hospital Colorado Experimental Therapeutics Program||Children's Hospital Colorado / Lia Gore, MD||Phase I/II Infrastructure Grants||2013||Colorado|
|Nationwide Children's Hospital Phase I/II Infrastructure||Research Institute at Nationwide Children's Hospital / Sarah O'Brien, MD and Timothy Cripe, MD, PhD||Phase I/II Infrastructure Grants||2013||Ohio|
|Pre-Clinical Testing of T cells Coded with CARs for DIPG||University of Texas / Laurence Cooper, MD, PhD||Innovation Grants||2013||Texas|
|Next-Generation Therapies for Hedgehog Pathway-Dependent Tumors||Lucile Packard Children's Hospital at Stanford University School of Medicine / James Chen, PhD||Innovation Grants||2013||California|
|Epigenetic Characterization of the Neuroblastoma Driver Genes ARID1A and ARID1B||Children's Hospital of Philadelphia / Michael Hogarty, MD||Innovation Grants||2013||Pennsylvania|
|Therapeutically Targeting a Tumor Suppressor Complex in Aggressive Pediatric Cancers||Dana-Farber Cancer Institute / Charles Roberts, MD, PhD||Innovation Grants||2013||Massachusetts|
|Reactivating Apoptosis in Refractory Pediatric Cancer by Molecular Inhibition of MCL-1||Dana-Farber Cancer Institute / Loren Walensky, MD, PhD||Innovation Grants||2013||Massachusetts|
|Identification of TFAP4 (Transcription Factor AP-4/Activating Enhancer Binding Protein) as a Potential Master Regulator/Synthetic Lethal Gene of MYCN Amplified Neuroblastoma||Columbia University Medical Center / Darrell Yamashiro, MD, PhD||Innovation Grants||2013||New York|